Tickers

SSNC — Ticker Eval done nvidia/nemotron-3-ultra-550b-a55b:free

Requested 2026-09-25 06:10:13.322344 UTC · finished 2026-09-25 06:11:18.073980 UTC

1. Composite Trajectory Verdict

For a software-enabled services business with high recurring revenue, all three statements carry roughly equal weight: the income statement shows the profitability of the recurring base, the cash flow statement reveals the conversion of that base into discretionary cash, and the balance sheet reflects the leverage used to fund acquisitions and shareholder returns.

Composite Trajectory: Improving

Revenue grew 6.6% in FY2025 to $6,272.2M and 10.3% YoY in Q2 2026 to $1,695.7M (10-K FY2025, Consolidated Statements of Operations; 10-Q Q2 2026, MD&A). Gross margin held near 48% across both annual and quarterly periods (10-K FY2025, Consolidated Statements of Operations; 10-Q Q2 2026, MD&A). Operating income rose 6.9% annually to $1,436.7M (10-K FY2025, Consolidated Statements of Operations). Net income attributable to common stockholders increased 4.9% to $796.9M and diluted EPS rose 5.0% to $3.15 (10-K FY2025, Consolidated Statements of Operations). Operating cash flow surged 25.7% to $1,744.8M in FY2025 (10-K FY2025, Consolidated Statements of Cash Flows). Net secured leverage remained low at 1.70x versus a 6.25x covenant (10-K FY2025, MD&A). Equity grew to $6.9B while debt increased to fund acquisitions (10-K FY2025, Consolidated Balance Sheets). No statement shows deterioration; all three show consistent improvement.

2. Red Flags

  • Equity in earnings of unconsolidated affiliates swung from a $100.0M gain in FY2023 to $24.4M in FY2024 to a $(9.3)M loss in FY2025, driven largely by Orbit Private Investments L.P. (10-K FY2025, Consolidated Statements of Comprehensive Income; Note 7).
  • Other (expense) income, net deteriorated from $20.7M income in FY2023 to $8.9M in FY2024 to $(23.0)M expense in FY2025, including a $35.1M loss on sale of fixed assets in FY2025 (10-K FY2025, Consolidated Statements of Comprehensive Income; MD&A).
  • Effective tax rate volatile: 29.0% (FY2023), 14.8% (FY2024), 18.1% (FY2025) due to discrete items (10-K FY2025, Consolidated Statements of Comprehensive Income; Note 17).
  • Client funds obligations grew to $3,799.5M at FY2025, up from $3,162.2M at FY2024, creating a large gross liability matched by restricted assets (10-K FY2025, Consolidated Balance Sheets).
  • Goodwill of $9,991.3M represents 48% of total assets at FY2025; while no impairment was recorded, the balance is sensitive to acquisition performance (10-K FY2025, Consolidated Balance Sheets; Note 9).
  • Share repurchases of $1,036.0M in FY2025 were partially funded by $1,050.0M of incremental Term B-8 debt for the Calastone acquisition (10-K FY2025, Consolidated Statements of Cash Flows; MD&A).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Total revenue increased 6.6% YoY to $6,272.2M in FY2025 and 10.3% YoY to $1,695.7M in Q2 2026 (10-K FY2025, Consolidated Statements of Operations; 10-Q Q2 2026, MD&A). Software-enabled services revenue, 83% of the mix, grew 7.7% annually and 11.1% in Q2 2026 (10-K FY2025, MD&A; 10-Q Q2 2026, MD&A). Gross margin remained stable at 48.2% (FY2025) and 48.3% (Q2 2026) (10-K FY2025, Consolidated Statements of Operations; 10-Q Q2 2026, MD&A). Total operating expenses as a percentage of revenue declined to 25.3% in FY2025 from 25.8% in FY2024 (10-K FY2025, MD&A). Operating income rose 6.9% to $1,436.7M in FY2025 (10-K FY2025, Consolidated Statements of Operations). Net income attributable to common stockholders rose 4.9% to $796.9M; diluted EPS rose 5.0% to $3.15 (10-K FY2025, Consolidated Statements of Operations). Interest expense declined to $434.7M in FY2025 from $463.0M in FY2024 (10-K FY2025, Consolidated Statements of Comprehensive Income).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Net cash provided by operating activities increased 25.7% to $1,744.8M in FY2025 from $1,388.6M in FY2024 (10-K FY2025, Consolidated Statements of Cash Flows). Capital expenditures rose to $80.8M and capitalized software to $221.9M in FY2025 (10-K FY2025, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow less capex and capitalized software) approximately $1,442M in FY2025, up from approximately $1,133M in FY2024 (10-K FY2025, Consolidated Statements of Cash Flows). Cash used in financing activities was $243.5M in FY2025, driven by $1,036.0M of share repurchases and $253.8M of dividends, partially offset by $421.9M net borrowings and $425.5M of stock option proceeds (10-K FY2025, Consolidated Statements of Cash Flows). Cash and equivalents (including restricted and client funds) ended FY2025 at $3,573.8M, up $203.3M from FY2024 (10-K FY2025, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Stable

Total assets grew to $20,711.7M at FY2025 from $19,044.7M at FY2024, driven by goodwill ($9,991.3M vs $9,218.1M) and intangible assets from acquisitions (10-K FY2025, Consolidated Balance Sheets). Total debt (senior secured facilities plus senior notes) increased to $7,433.4M from $7,009.6M (10-K FY2025, Note 10). Cash, cash equivalents, and restricted cash (including client funds) rose to $3,573.8M from $3,370.5M (10-K FY2025, Consolidated Balance Sheets). Client funds obligations grew to $3,799.5M from $3,162.2M (10-K FY2025, Consolidated Balance Sheets). Total SS&C stockholders' equity increased to $6,887.6M from $6,534.9M (10-K FY2025, Consolidated Balance Sheets). Net secured leverage ratio per the credit agreement was 1.70x at FY2025, well below the 6.25x covenant maximum (10-K FY2025, MD&A). The company remained in compliance with all financial and non-financial covenants (10-K FY2025, Note 10).

6. Data Gaps

  • Quarterly cash flow statements for Q2 2026 (six months ended June 30, 2026) are not fully visible in the provided 10-Q excerpt; only operating, investing, and financing summaries for FY periods are complete.
  • Q3 2026 and Q4 2026 quarterly results are not yet filed; FY2026 full-year results are not available.
  • Organic revenue growth rates for FY2025 and FY2024 are disclosed in MD&A but not broken out by quarter in the provided 10-Qs for direct YoY quarterly comparison beyond Q2.
  • Segment-level profitability is not reported; the company operates in one reportable segment (10-K FY2025, Note 19).
  • Detailed working capital changes (accounts receivable, contract assets, deferred revenue) for Q2 2026 are not provided in the excerpt.
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short. JSON: /api/signals · /api/funds · /api/status